Loading…
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $152M | $1M | $-12M | $1M | -13.3% | -15.8% | - |
| 2024 | $180M | $10M | $-8M | $-3M | -10.3% | -7.9% | - |
| 2023 | $196M | $20M | $-4M | $14M | -5.0% | 16.1% | - |
| 2022 | $169M | $4M | $-15M | $12M | -20.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 168.79 | 195.92 | 180.35 | 151.82 |
| Cost Of Revenue | 62.78 | 73.77 | 71.15 | 61.69 |
| Gross Profit | 106.01 | 122.14 | 109.20 | 90.13 |
| Operating Expense | 109.48 | 112.63 | 110.77 | 94.96 |
| Operating Income | -3.47 | 9.51 | -1.57 | -4.83 |
| EBITDA | 3.52 | 19.98 | 10.30 | 1.22 |
| EBIT | -4.54 | 9.72 | -1.58 | -11.56 |
| Pretax Income | -11.30 | 3.24 | -7.83 | -17.64 |
| Tax Provision | 3.38 | 7.48 | 0.19 | -5.97 |
| Net Income | -14.68 | -4.24 | -8.02 | -11.67 |
| Net Income Common Stockholders | -14.68 | -4.24 | -8.02 | -11.67 |
| Total Expenses | 172.26 | 186.41 | 181.92 | 156.65 |
| Interest Expense | 6.75 | 6.49 | 6.25 | 6.08 |
| Selling General And Administration | 101.42 | 102.38 | 98.88 | 82.18 |
| Normalized EBITDA | 4.59 | 19.76 | 10.32 | 7.95 |
| Normalized Income | -13.83 | -4.41 | -8.01 | -7.21 |
| Basic EPS | -0.26 | -0.08 | -0.14 | 0 |
| Diluted EPS | -0.26 | -0.08 | -0.14 | 0 |
| Tax Effect Of Unusual Items | -0.23 | 0.04 | 0 | -2.27 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.34 |
| Total Unusual Items | -1.08 | 0.21 | -0.02 | -6.73 |
| Total Unusual Items Excluding Goodwill | -1.08 | 0.21 | -0.02 | -6.73 |
| Net Income From Continuing Operation Net Minority Interest | -14.68 | -4.24 | -8.02 | -11.67 |
| Reconciled Depreciation | 8.06 | 10.25 | 11.89 | 12.78 |
| Reconciled Cost Of Revenue | 62.78 | 73.77 | 71.15 | 61.69 |
| Net Interest Income | -6.75 | -6.49 | -6.25 | -6.08 |
| Net Income From Continuing And Discontinued Operation | -14.68 | -4.24 | -8.02 | -11.67 |
| Total Operating Income As Reported | -4.54 | 9.72 | -1.58 | -11.56 |
| Diluted Average Shares | 55.68 | 56.78 | 57.69 | 0 |
| Basic Average Shares | 55.68 | 56.78 | 57.69 | 0 |
| Diluted NI Availto Com Stockholders | -14.68 | -4.24 | -8.02 | -11.67 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -14.68 | -4.24 | -8.02 | -11.67 |
| Net Income Continuous Operations | -14.68 | -4.24 | -8.02 | -11.67 |
| Other Income Expense | -1.08 | 0.21 | -0.02 | -6.73 |
| Special Income Charges | -1.08 | 0.21 | -0.02 | -6.73 |
| Gain On Sale Of Ppe | -0.15 | 0.21 | -0.02 | 0 |
| Gain On Sale Of Business | 0 | 0 | 0 | -2.15 |
| Other Special Charges | 0.93 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 0.15 | -0.21 | 0.02 | 4.58 |
| Net Non Operating Interest Income Expense | -6.75 | -6.49 | -6.25 | -6.08 |
| Interest Expense Non Operating | 6.75 | 6.49 | 6.25 | 6.08 |
| Depreciation Amortization Depletion Income Statement | 8.06 | 10.25 | 11.89 | 12.78 |
| Depreciation And Amortization In Income Statement | 8.06 | 10.25 | 11.89 | 12.78 |
| Operating Revenue | 168.79 | 195.92 | 180.35 | 151.82 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| AirSculpt Technologies, Inc.this co. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Quantum-Si incorporated | QSI | $187M | - | 0.85 | -46.0% | -0.31 |
| KORU Medical Systems, Inc. | KRMD | $185M | - | 10.79 | -15.5% | -78.39 |
| Humacyte, Inc. | HUMA | $182M | - | 51.25 | -1313.4% | -1.97 |
| Korro Bio, Inc. | KRRO | $182M |
| - |
| 2.31 |
| -228.0% |
| -1.81 |
| CVRx, Inc. | CVRX | $181M | - | 4.60 | -135.6% | -3.08 |
| Stereotaxis, Inc. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $176M | - | 0.65 | -50.6% | 0.32 |
| Alpha Teknova, Inc. | TKNO | $173M | - | 2.52 | -25.1% | -17.76 |
| Peer Median | - | - | 3.56 | -83.1% | -2.52 | |